[Skip to Content]
[Skip to Content Landing]
March 1979

Quantitative Enhancement of Dinitrochlorobenzene Responsivity in Women Receiving Oral Contraceptives

Author Affiliations

From the Section of Dermatology, Department of Medicine, University of Southern California School of Medicine, and the Department of Dermatology, Los Angeles County-University of Southern California Medical Center, Los Angeles.

Arch Dermatol. 1979;115(3):361-362. doi:10.1001/archderm.1979.04010030063025

Enhancement of dinitrochlorobenzene (DNCB) responsivity by estrogen-progestin combination oral contraceptives or by parenteral progestins was reported by Gerretsen et al.1 Because of a possible influence of contraceptive use on either controls or patients in studies using DNCB, this observation warranted attempted confirmation. Furthermore, the apparent but unexplained protective effect of oral contraceptive use on the incidence of rheumatoid arthritis emphasized the importance of careful study of any immunologic influence of this widely used medication.2

Patients and Methods  Sensitization with DNCB was attempted in 13 women receiving estrogen-progestin combination oral contraceptives for the purpose of contraception, 20 women of similar ages receiving neither estrogens nor progestins, and 16 men of similar ages. The subjects were clinic patients, hospital employees, or medical students judged to be in good general health, without disease, and not taking medications known to influence immunologic responses. Blacks were not included in this study because of

First Page Preview View Large
First page PDF preview
First page PDF preview